| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1268 |
| Trial ID | NCT00446381 |
| Disease | Diabetic Macular Edema | Proliferative Diabetic Retinopathy |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Phase | Not Applicable |
| Recruitment status | Completed |
| Title | Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME) |
| Year | 2006 |
| Country | Canada |
| Company sponsor | Lawson Health Research Institute |
| Other ID(s) | R-06-821|Health Canada Control #108753 |
| Cohort1: Patients with Proliferative Diabetic Retinopathy | |||||||
|
|||||||
| Cohort2: Patients with Clinically Significant Macular Edema | |||||||
|
|||||||